Zephyr Platform

The Zephyr Platform is a multi-modal AI and real-world data platform designed to transform complex biomedical data into actionable insights for precision medicine. Built for biopharma, diagnostics, and clinical partners, it combines enterprise-scale real-world data, deeply profiled oncology cohorts, and biologically interpretable AI to de-risk drug development, optimize patient selection, and accelerate clinical translation—spanning the full journey from discovery to deployment.

Zephyr's platform bridges experimental and clinical domains, extracting hidden signals from large multi-modal datasets to deliver insights enriched with deep biological context shaped by learnings across vast drug, tumor, and patient landscapes. All solutions integrate seamlessly into partner workflows and are built on secure, SOC 2 and HIPAA compliant infrastructure designed for pharma-grade speed and scale.

AIM Suite: Modular Multi-Modal AI for Precision Oncology

• AIM-Bx & AIM-io: Predict response to small molecules or immune checkpoint inhibitors using clinically available data. Validated in real-world cohorts, these modules outperform conventional biomarkers and can be adapted as AI-companion diagnostics for partner drugs.
• AIM-CDx: Fine-tuned companion diagnostics co-developed with biopharma and diagnostics partners. Built on AIM-Bx and adapted to partner assays and assets using preclinical or clinical data.
• AIM-Ex: Reconstructs mRNA expression from DNA-based laboratory-developed tests and minimal clinical data with high concordance to RNAseq, enhancing interpretability and feeding downstream models with biologically rich expression-level inputs.
• Each module can operate independently or in combination, giving partners the flexibility to tailor solutions to their specific drug development or clinical needs—no new assays required.

Nexus: Real-World Intelligence at Scale

• Analytics & Insights: Extract intelligence from a database of 90 million or more patients across oncology—including over one million with next-generation sequencing data—and chronic disease populations.
• Cohort Construction & Synthetic Controls: Define fit-for-purpose patient populations and credible comparator arms for clinical trials and health economics and outcomes research (HEOR).
• AI/ML Modeling & Validation: Train, test, and refine predictive models on linked longitudinal data drawn from EHR, claims, genomics, and pathology sources.
• Intervention-Specific Risk Modeling: Predict outcomes and costs to inform pricing, market access, and value-based care strategies.

Deep Oncology Data: Curated, Consented Cancer Cohorts

• Through Aster Insights™ and the ORIEN Total Cancer Care® study, Zephyr provides access to one of the largest and most deeply profiled oncology resources in the world, encompassing over 400,000 lifetime-consented patients across leading cancer centers.
• Linked, Multi-Modal Profiles (Aster Avatar): Matched clinical, exome, transcriptome, and digital pathology data with longitudinal updates, ideal for translational research and biomarker discovery.
• Fit-for-Purpose Data Generation: New molecular data can be generated to power discovery, validation, and regulatory programs tailored to partner needs.

Enterprise-Grade Infrastructure for Speed and Scale

• SOC 2 and HIPAA compliant infrastructure ensures partner data is handled securely and responsibly, going beyond academic or point-solution approaches.
• Modern ML Ops lifecycle management and deployment systems enable models to move seamlessly from concept to production.
• Proof-of-concept pilots can be launched in weeks and scaled to clinical and commercial applications without re-engineering.

Key Platform Differentiators

• Clinically validated across diverse, real-world patient cohorts
• Seamlessly compatible with existing diagnostics—no new assays required
• Biologically interpretable outputs that support trust and regulatory alignment
• Flexible and adaptable for retrospective or prospective validation, fine-tuned to partner drugs or laboratory-developed tests
• Fast to start and scalable to impact, with pilots launching in weeks

The Zephyr Platform is designed for biopharma and diagnostics partners seeking to co-develop precision medicine solutions at scale. With SOC 2 and HIPAA compliance, modern MLOps infrastructure, and seamless integration into existing partner workflows, Zephyr supports the full spectrum of use cases from early discovery through clinical and commercial deployment.